Payment overview · 2025
General Payments
$883.34
49 reported records · 17 companies
Healthcare provider profile · identity verified
Ira Lyman Mitchell, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FLORENCE, AL · NPI 1881776078
Verified facts
What the public records show
CMS Open Payments records show Ira Lyman Mitchell, M.D. received $883.34 in general payments during 2025 across 49 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulance by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $199.33 | 22.6% | 11 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $119.02 | 13.5% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $93.78 | 10.6% | 6 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $71.15 | 8.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $64.65 | 7.3% | 4 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $60.31 | 6.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.90 | 6.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.94 | 4.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.92 | 3.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.04 | 3.6% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $20.55 | 2.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.04 | 2.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.91 | 1.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.14 | 1.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.10 | 1.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.97 | 1.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.59 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $883.34 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $133.38 | 7 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $119.02 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $93.78 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $71.43 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $71.15 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $64.65 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $64.65 | 4 | 2025 |
Source payment records
|
|||||
| Veklury Normalized: veklury |
Drug | Gilead Sciences, Inc. | $60.31 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $54.90 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.94 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $35.58 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $33.92 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.92 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.04 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.97 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 46 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 185 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 107 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 65 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
107 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
185 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
65 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
185 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
107 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1117 | 175 |
| Gabapentin | Gabapentin | 981 | 153 |
| Alprazolam | Alprazolam | 840 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 597 | 170 |
| Pantoprazole Sodium | Pantoprazole Sodium | 578 | 158 |
| Montelukast Sodium | Montelukast Sodium | 539 | 167 |
| Atorvastatin Calcium | Atorvastatin Calcium | 492 | 151 |
| Tramadol Hcl | Tramadol Hcl | 474 | 83 |
| Omeprazole | Omeprazole | 470 | 123 |
| Meloxicam | Meloxicam | 428 | 126 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 417 | 140 |
| Temazepam | Temazepam | 395 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 380 | 118 |
| Losartan Potassium | Losartan Potassium | 323 | 98 |
| Zolpidem Tartrate | Zolpidem Tartrate | 323 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 320 | 100 |
| Eliquis | Apixaban | 284 | 60 |
| Torsemide | Torsemide | 284 | 82 |
| Cefdinir | Cefdinir | 282 | 204 |
| Pregabalin | Pregabalin | 277 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 266 | 72 |
| Potassium Chloride | Potassium Chloride | 256 | 74 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 252 | 36 |
| Metformin Hcl | Metformin Hcl | 249 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 236 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 63 |
| Simvastatin | Simvastatin | 221 | 73 |
| Furosemide | Furosemide | 214 | 61 |
| Citalopram Hbr | Citalopram Hydrobromide | 193 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 188 | 48 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 187 | 48 |
| Jardiance | Empagliflozin | 185 | 34 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 182 | 46 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 178 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 47 |
| Clonazepam | Clonazepam | 161 | 20 |
| Lorazepam | Lorazepam | 159 | 23 |
| Trazodone Hcl | Trazodone Hcl | 149 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 146 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 143 | 42 |
| Methocarbamol | Methocarbamol | 142 | 39 |
| Dicyclomine Hcl | Dicyclomine Hcl | 141 | 49 |
| Allopurinol | Allopurinol | 135 | 44 |
| Diazepam | Diazepam | 133 | 19 |
| Azelastine Hcl | Azelastine Hcl | 132 | 83 |
| Ondansetron Odt | Ondansetron | 131 | 64 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 129 | 18 |
| Donepezil Hcl | Donepezil Hcl | 128 | 32 |
| Carvedilol | Carvedilol | 123 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 122 | 40 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 121 | 30 |
| Buspirone Hcl | Buspirone Hcl | 118 | 29 |
| Metformin Hcl Er | Metformin Hcl | 118 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 37 |
| Lisinopril | Lisinopril | 114 | 37 |
| Valsartan | Valsartan | 113 | 33 |
| Meclizine Hcl | Meclizine Hcl | 111 | 49 |
| Diclofenac Sodium | Diclofenac Sodium | 110 | 38 |
| Mounjaro | Tirzepatide | 107 | 25 |
| Synthroid | Levothyroxine Sodium | 107 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 38 |
| Eszopiclone | Eszopiclone | 102 | 21 |
| Januvia | Sitagliptin Phosphate | 101 | 22 |
| Ezetimibe | Ezetimibe | 100 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 37 |
| Irbesartan | Irbesartan | 98 | 31 |
| Prednisone | Prednisone | 98 | 49 |
| Spironolactone | Spironolactone | 88 | 26 |
| Mupirocin | Mupirocin | 85 | 55 |
| Promethazine Hcl | Promethazine Hcl | 84 | 19 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 82 | 26 |
| Finasteride | Finasteride | 82 | 24 |
| Estradiol | Estradiol | 80 | 25 |
| Nabumetone | Nabumetone | 79 | 20 |
| Cephalexin | Cephalexin | 77 | 40 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 76 | 17 |
| Sertraline Hcl | Sertraline Hcl | 76 | 19 |
| Aripiprazole | Aripiprazole | 73 | 22 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 73 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 23 |
| Celecoxib | Celecoxib | 71 | 19 |
| Megestrol Acetate | Megestrol Acetate | 71 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 71 | 53 |
| Quetiapine Fumarate | Quetiapine Fumarate | 70 | 14 |
| Methylprednisolone | Methylprednisolone | 69 | 53 |
| Ibuprofen | Ibuprofen | 67 | 27 |
| Azithromycin | Azithromycin | 66 | 54 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 66 | 40 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 66 | 36 |
| Mirtazapine | Mirtazapine | 66 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 64 | 16 |
| Fluconazole | Fluconazole | 62 | 47 |
| Benazepril Hcl | Benazepril Hcl | 59 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 15 |
| Glimepiride | Glimepiride | 58 | 18 |
| Memantine Hcl | Memantine Hcl | 57 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 14 |
| Famotidine | Famotidine | 51 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 14 |
| Ozempic | Semaglutide | 51 | 12 |
| Ketoconazole | Ketoconazole | 49 | 27 |
| Levetiracetam | Levetiracetam | 48 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 15 |
| Entresto | Sacubitril/Valsartan | 47 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 46 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 45 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | 13 |
| Fenofibrate | Fenofibrate | 41 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 41 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 40 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 40 | 11 |
| Clonidine Hcl | Clonidine Hcl | 40 | 11 |
| Levofloxacin | Levofloxacin | 40 | 34 |
| Primidone | Primidone | 40 | 12 |
| Atenolol | Atenolol | 39 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 36 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Topiramate | Topiramate | 35 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 11 |
| Baclofen | Baclofen | 33 | suppressed |
| Hydrocortisone | Hydrocortisone | 33 | 13 |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Premarin | Estrogens, Conjugated | 32 | suppressed |
| Sotalol | Sotalol Hcl | 32 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 31 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 30 | suppressed |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 30 | 11 |
| Valacyclovir | Valacyclovir Hcl | 30 | 23 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 29 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 28 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 11 |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 22 |
| Pentoxifylline | Pentoxifylline | 26 | suppressed |
| Zaleplon | Zaleplon | 26 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Nystatin | Nystatin | 25 | 17 |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 20 |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Ramipril | Ramipril | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Verapamil Sr | Verapamil Hcl | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Quviviq | Daridorexant Hcl | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Trulance | Plecanatide | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Trandolapril | Trandolapril | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $883.34 · 49 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, Cologuard Collection Kit, FARXIGA, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, QULIPTA, REPATHA, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, Veklury, XIFAXAN | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error